Sivanesan S, Ramberg H, Kristiansen T, Thapa SB, Bjøre M, Berge V, Ottosson F, Brennhovd B, Storås AMH, Thorsby PM, Dahl SR, Urbanucci A, Grytli HH, Bjerke L, Taskén KA (2026)
Perioperative propranolol during robotic-assisted radical prostatectomy: A randomised, double-blind, placebo-controlled, pilot trial (PeP-RALP)
BJUI Compass, 7 (9), e70267
DOI 10.1002/bco2.70267, PubMed 42662047

Doultsinos D, Tomljanovic I, Pilalis E, Abusamra SM, Alshalalfa M, Parmentier R, Ahire V, Bridges IE, Figiel S, Hester J, Leach D, Nandakumar A, Wan R, Zekri Y, Zhang J, Bevan CL, O'Neill E, Lamb AD, Macauley V, Theurillat JP, Urbanucci A, Karnes RJ, Spratt DE, Davicioni E, Quigley D, Zwart W, Le Magnen C, Chatziioannou A, Mills IG (2026)
IRE1 activity is prognostic in localised and metastatic prostate cancer and affects epithelial lineage states
EMBO Mol Med (in press)
DOI 10.1038/s44321-026-00490-w, PubMed 42632837

Erkan EP, Hämäläinen E, Kolikova J, Nikupaavola T, Sajnani K, Kuc K, Ojala K, Kukkonen M, Hermelo I, Kurttila A, Koskensalo S, Tarvainen T, Leppä A, Keränen I, Haapamäki C, Karjalainen E, Carpelan-Holmström M, Renkonen-Sinisalo L, Koskenvuo L, Puolakkainen P, Mecklin JP, Väyrynen JP, Virolainen E, iCAN, Nykter M, Aaltonen LA, Urbanucci A, Lepistö A, Ristimäki A, Seppälä TT (2026)
Epithelial interferon-stimulated gene programs modulate chemotherapy sensitivity in colorectal cancer via EPSTI1
Oncogene (in press)
DOI 10.1038/s41388-026-03957-9, PubMed 42629443